Therapeutic potential of ciclesonide inahalation for COVID-19 pneumonia: Report of three cases

被引：83

作者：

Iwabuchi, Keisuke ^{[1
]}

Yoshie, Koichiro ^{[1
]}

Kurakami, Yuichi ^{[1
]}

Takahashi, Kota ^{[1
]}

Kato, Yoshio ^{[1
]}

Morishima, Tsuneo ^{[2
,3
]}

机构：

[1] Kanagawa Prefectural Ashigarakami Hosp, Dept Gen Med, 866-1 Matsuda Soryo,Matsuda Machi, Ashigarakami, Kanagawa 2580003, Japan

[2] Aichi Med Univ, Nagakute, Aichi, Japan

[3] AMED Study Diag & Treatment Methods Serious Viral, Tokyo, Japan

来源：

JOURNAL OF INFECTION AND CHEMOTHERAPY | 2020年 / 26卷 / 06期

关键词：

Ciclesonide; Inhalation; Coronavirus disease 2019;

D O I：

10.1016/j.jiac.2020.04.007

中图分类号：

R51 [传染病];

学科分类号：

100201 [内科学];

摘要：

No specific and effective anti-viral treatment has been approved for COVID-19 so far. Systemic corticosteroid has been sometimes administered to severe infectious diseases combined with the specific treatment. However, as lack of the specific anti-SARS-CoV-2 drug, systemic steroid treatment has not been recommended for COVID-19. We report here three cases of the COVID-19 pneumonia successfully treated with ciclesonide inhalation. Rationale of the treatment is to mitigate the local inflammation with inhaled steroid that stays in the lung and to inhibit proliferation of the virus by antiviral activity. Larger and further studies are warranted to confirm the result of these cases. (C) 2020 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

引用

页码：625 / 632

页数：8